Drugs / HS-10345
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05196971 | Oct 2021 → Apr 2022 | major depressive disorder | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10345 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05196971 ↗ |
| Route | Intranasal | “self-administered as an intranasal formulation” NCT05196971 ↗ |